Literature DB >> 23552723

Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Mårten Wendt1, Ola Börjesson, Aune Avik, Johan Bratt, Björn Anderstam, Abdul R Qureshi, Edmund J Miller, Iva Gunnarsson, Annette Bruchfeld.   

Abstract

Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine known to be released from lymphocytes, macrophages and endothelial cells and also in animal models shown to be inducible with glucocorticoids (GC). In contrast, thyroxine seems to antagonize MIF activity. To investigate whether MIF is increased in active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and possible correlations with GC dosing and thyroid hormone levels, 27 consecutive patients with active AAV were studied and followed prospectively. Disease activity was assessed using Birmingham Vasculitis Activity Score 2003 (BVAS) at baseline and at follow-up at 3 and 6 months, along with MIF, thyroid hormones free triiodothyronine (fT3) and free thyroxine (fT4), C-reactive protein (CRP) and creatinine. MIF was elevated significantly at baseline compared with follow-up at 3 and 6 months (8,618 pg/mL versus 5,696 and 6,212 respectively; P < 0.002) but did not correlate to CRP, GC dose, creatinine or organ involvement. fT3 was depressed significantly at baseline compared with follow-up (1.99 pg/mL versus 2.31 and 2.67 respectively; P = 0.01) and correlated inversely to the BVAS score at baseline. We found a significant correlation between the MIF/fT4 ratio at baseline versus MIF/fT4 ratio at 6 months (ρ = 0.52, P < 0.005) and a trend between the baseline MIF/fT3 ratio versus MIF/fT3 ratio at 6 months (ρ = 0.39, P = 0.05). These results suggest a possible role for MIF and thyroid status in AAV. Further studies could reveal whether the association between AAV and thyroid hormone levels in the context of elevated MIF may present a link as well as a target of treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23552723      PMCID: PMC3667215          DOI: 10.2119/molmed.2012.00352

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  30 in total

Review 1.  ANCA disease: where is this field heading?

Authors:  Ronald J Falk; J Charles Jennette
Journal:  J Am Soc Nephrol       Date:  2010-04-15       Impact factor: 10.121

Review 2.  Macrophage migration inhibitory factor (MIF): a promising biomarker.

Authors:  Gerrit Grieb; Melanie Merk; Jürgen Bernhagen; Richard Bucala
Journal:  Drug News Perspect       Date:  2010-05

3.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

4.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

5.  Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides.

Authors:  Heidemarie Becker; Christian Maaser; Eva Mickholz; Anke Dyong; Wolfram Domschke; Markus Gaubitz
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

Review 6.  Autoimmune diseases: MIF as a therapeutic target.

Authors:  Dorothee Greven; Lin Leng; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2010-03       Impact factor: 6.902

7.  Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study.

Authors:  Marjan C Slot; Thera P Links; Coen A Stegeman; Jan Willem Cohen Tervaert
Journal:  Arthritis Rheum       Date:  2005-02-15

8.  Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.

Authors:  Annette Bruchfeld; Juan J Carrero; Abdul R Qureshi; Bengt Lindholm; Peter Barany; Olof Heimburger; Maowen Hu; Xinchun Lin; Peter Stenvinkel; Edmund J Miller
Journal:  Mol Med       Date:  2009-12-08       Impact factor: 6.354

Review 9.  Macrophage migration inhibitory factor in cardiovascular disease.

Authors:  Alma Zernecke; Jürgen Bernhagen; Christian Weber
Journal:  Circulation       Date:  2008-03-25       Impact factor: 29.690

10.  Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study.

Authors:  Sofia Lionaki; Susan L Hogan; Ronald J Falk; Melanie S Joy; Hyunsook Chin; Caroline E Jennette; J Charles Jennette; Patrick H Nachman
Journal:  Nephrol Dial Transplant       Date:  2007-08-08       Impact factor: 5.992

View more
  4 in total

1.  Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis.

Authors:  Antoine G Sreih; Rana Ezzedine; Lin Leng; Juan Fan; Jie Yao; Duncan Reid; Marta Piecychna; Simon Carette; David Cuthbertson; Paul Dellaripa; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Alfred Mahr; Carol A McAlear; Kathleen Maksimowicz-Mckinnon; Paul A Monach; Philip Seo; Ulrich Specks; E William St Clair; John H Stone; Steven R Ytterberg; Jeffrey Edberg; Peter A Merkel; Richard Bucala
Journal:  Arthritis Rheumatol       Date:  2018-10-22       Impact factor: 10.995

Review 2.  Macrophage Migration Inhibitory Factor in Clinical Kidney Disease.

Authors:  Annette Bruchfeld; Mårten Wendt; Edmund J Miller
Journal:  Front Immunol       Date:  2016-01-26       Impact factor: 7.561

3.  Macrophage migration inhibitory factor is involved in antineutrophil cytoplasmic antibody-mediated activation of C5a-primed neutrophils.

Authors:  Jian Hao; Tiegang Lv; Liping Xu; Mao Ran; Kaili Wu
Journal:  BMC Immunol       Date:  2019-06-27       Impact factor: 3.615

4.  Dual effect of a polymorphism in the macrophage migration inhibitory factor gene is associated with new-onset Graves disease in a Taiwanese Chinese population.

Authors:  Yu-Huei Liu; Ching-Chu Chen; Chen-Ming Yang; Yi-Ju Chen; Fuu-Jen Tsai
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.